LiverRight reaches patients and advocates in the liver disease community. This coverage is significant because it highlights a critical gap: 80–90% of at-risk patients currently don't get screened, and HelioLiver addresses this with a simple blood draw.
LiverRight covers the Helio Genomics and Quest Diagnostics partnership, emphasizing that liver cancer incidence has tripled and mortality has doubled, yet 80–90% of at-risk patients don't get screened. The article highlights how HelioLiver combines cell-free DNA methylation analysis, protein biomarkers, and AI to detect cancer signals 'earlier than imaging alone' and notes that blood-based liver cancer screening is 'moving toward mainstream clinical adoption at scale.'